Horizon Discovery, a Cambridge, UK-based translational genomics and personalized medicine company, has closed a £6.25m Series C financing.
The round was led by venture capital firm DFJ Esprit, with participation from existing investors Roche Venture Fund, Dr Jonathan Milner and Mr David Evans.
Horizon has also announced the following appointments to its board of directors:
– Dr Nigel Pitchford, Partner at DFJ Esprit, will join as Investor Director. He has extensive experience in investing in healthcare both at DFJ Esprit and previously at 3i where he led the venture team’s healthcare activities across Europe and the US.
– Mr David Evans will join as a Non-Executive Director. He is Chairman of Immunodiagnostics Systems and has considerable expertise within the diagnostic industry.
The company provides its customers with biological tools and services that aim to accelerate the pace of development of “stratified” or “personalized” medicines. These new funds will enable Horizon to further improve its core GENESIS™ and X-MAN™ technology platforms, address new markets, and begin to target therapeutics markets outside of its historical cancer-focus.